Understanding how antibody treatments work in different biological environments
Official title: Quantitative Systems Pharmacology of Antibody Therapeutics across Diverse Biological Contexts
Funded at Univ of North Carolina Chapel Hill · NIH-11015786 · Data updated 2026-11-12
This study is looking at how antibody treatments work differently in various parts of the body and how our immune system responds, with the goal of helping patients get more effective treatments tailored to their specific needs.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Univ of North Carolina Chapel Hill NIH-funded |
| Lab location | 1 site (Chapel Hill, United States) |
| Project start | February 1, 2024 |
| Project end | January 31, 2029 |
| Funding year | 2025 |
| Award (this year) | $352,921 |
| NIH project number | 5R35GM152449-02 |
| Project ID | NIH-11015786 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals receiving or considering antibody-based treatments for various conditions.
✕Less likely to help
Patients who are not receiving antibody therapies or those with conditions not addressed by antibody treatments may not benefit from this research.
What this research studies
This research investigates the pharmacology of antibody-based therapies, focusing on how their effectiveness can vary depending on the biological context in which they are used. By developing advanced models and experimental tools, the research aims to analyze factors such as tissue-specific drug behavior and immune responses. Patients may benefit from a better understanding of how these therapies can be optimized for individual conditions, potentially leading to more effective treatments. The study seeks to address the high failure rates in antibody drug development by providing insights into the complex interactions that influence treatment outcomes.
Why it matters
Potential benefit: If successful, this research could lead to more effective and personalized antibody therapies for patients.
How similar studies have gone: Previous research has shown promise in understanding antibody pharmacology, but this approach aims to refine and expand on those findings in a novel way.
Where this research is happening
-
Univ of North Carolina Chapel Hill
Chapel Hill, United States Active
Researchers
- Principal investigator: Cao, Yanguang — Univ of North Carolina Chapel Hill
- Study coordinator: Cao, Yanguang
Related research
Other NIH-funded projects on the same topics.
-
A center for coordinating data related to heart and blood health.
This study is working on a new system to gather and analyze health information about heart and blood disorders, which could lead to better ways to diagnose and treat these conditions, ultimately helping patients like you.
-
Healthy work design and worker well-being
A multi-site program aims to improve the health and well-being of workers by studying how work design affects safety, stress, and quality of life.
-
Unified and fair multimodal learning for autoimmune diseases
A patient-friendly AI approach will combine many kinds of health data to improve diagnosis and personalized care for autoimmune diseases, including lupus.
-
Structural factors linking minimum wage, COVID-19, and community violence
A long-term study will explore whether higher minimum wages and pandemic-related economic factors are connected to changes in violence in US communities.
-
Non-invasive tears biomarker for early Alzheimer's in LMICs
A low-cost, tear-based biomarker approach aims to detect early Alzheimer’s disease in older adults in Peru and similar settings.
-
How HPV interacts with our cells' DNA damage system and its effect on cancer
This project looks at how high-risk HPV uses the body’s DNA repair machinery to replicate and potentially drive cancer, with the goal of finding new antiviral and cancer-fighting approaches for people affected by HPV-related diseases.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.